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were recorded and their relationship to VRC was determined. There
were two patients with mild elevation in liver function tests not
necessitating discontinuation of VRCwith spontaneous normalization
of liver function tests while on VRC. There was one patient with
confusion, noted three days after the initiation of VRC while on
narcotics. The confusion resolved upon discontinuing VRC and
adjusting narcotics. VRC was not restarted due to resolution of
fever and engraftment. Unlike prior reports we did not observe any
skin rashes or visual disturbances. Our experience conﬁrms the
safety and tolerability of VRC in HSCT patients.
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OPEN-LABEL, RANDOMIZED COMPARISON OF DOLASETRON VERSUS
ONDANSETRON FOR PREVENTION OF NAUSEA AND VOMITING DUR-
ING HIGH-DOSE CHEMOTHERAPY AND STEM CELL TRANSPLANTATION
Mandanas, R.A.1, Beveridge, R.A.2, Rifkin, R.M.3, Wallace, H.J.4,
Greenspan, A.5, Spitzer, G.6, Guo, H.7, Asmar, L.7 1. Cancer Care
Associates, Oklahoma City, OK; 2. Fairfax-Northern Virginia Hema-
tology-Oncology, Fairfax, VA; 3. Rocky Mountain Cancer Centers, Den-
ver, CO; 4. Piedmont Hematology-Oncology Associates, Winston-Salem,
NC; 5. Central Indiana Cancer Centers, Indianapolis, IN; 6. Cancer
Centers of the Carolinas, Greenville, SC; 7. US Oncology, Houston, TX
5-HT3 antagonists are now the standard for the prevention of
nausea and vomiting during conventional dose highly emetogenic
chemotherapy. Little data are available for the routine use of these
agents in the high-dose chemotherapy (HDC) and transplant set-
tings. Between May 1997 and March 2001, 197 patients were
randomized to received either Dolasetron (D) at 100 mg IV and
100 mg PO 8-12 hours later or Ondansetron (O) at 32 mg IV and
8 mg PO 8-12 hours later during HDC regimens for breast cancer
(STAMP V, n  96, 48.7%), non-Hodgkin’s lymphoma (BEAC,
n  83, 42.1%), and Hodgkin’s disease (CBV, n  18, 9.1%). In
addition to the 5-HT3 antagonist all patients also received dexa-
methasone 10 mg IV daily and an antiemetic pump containing
benadryl, lorazepam and dexamethasone (BAD) delivered at a con-
tinuous rate with patient-controlled on-demand bolus doses as
needed. Results: 164 (83 in D, 81 in O) of 197 patients were
evaluable after completing a daily diary which also included a visual
assessment scoring (VAS) for degree of nausea. Complete response
(no vomiting episode and no use of rescue medications) occurred in
D  36.1% and O  39.5%; major response (1 or 2 episodes of
vomiting with no rescue medications) in D  26.5% and O 
25.9%; and treatment failure (2 or more episodes in a 24 hour
period not relieved by BAD boluses or use of or request for rescue
medications) in D  23% and O  22%; all comparisons not
showing any signiﬁcant differences (p  0.5910). More than 70%
of patients in each arm showed varying degrees of nausea by VAS
scale. Subgroup analyses also failed to show any statistical differ-
ence in responses and failures between D and O when used for any
particular HDC regimen studied. Conclusion: D and O at the
doses studied are equivalent in responses and failures for the
prevention of nausea and vomiting in HDC and stem cell trans-
plantation. More than 70% of patients at least achieve good control
of vomiting with these agents in combination with dexamethasone
and an antiemetic (BAD) infusion pump.
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ROLE OF MUSIC THERAPY-BASED RELAXATION VS. EXPRESSIVE READ-
ING INTERVENTIONS IN BLOOD MARROW STEM CELL TRANSPLANTA-
TION
Liesveld, J.L.1, Sahler, O.J.Z.1, Hunter, B.C.2, Huang, L.-S.1, Oliva,
R.1 1. University of Rochester, Rochester, NY; 2. Nazareth College,
Rochester, NY
Patients undergoing hematopoietic stem cell transplantation of-
ten experience signiﬁcant pain, nausea, or emesis despite prophy-
lactic and therapeutic pharmacologic interventions. A randomized
controlled pilot study at the University of Rochester has been
conducted to determine the effects of a music therapy-based re-
laxation/stress reduction intervention, compared to an active con-
trol condition (expressive reading), on side effects related to
chemo-or radiotherapy and to determine whether any positive or
negative effects on graft or immune reconstitution were inﬂuenced
by these interventions. A total of 96 patients were accrued to the
study; 32 received music therapy, 33 expressive reading, and 31 no
intervention beyond usual supportive care. There were no signif-
icant differences in demographic or baseline variables among the
groups. The music therapy group received an average of 5.59
intervention seessions (range 1-11) and the expresive reading
group 6.06 (1-17) (NS) during their inpatient stays. Neither the
intervention nor the number of intervention sessions received
affected average number of days to engraftment or days to dis-
charge. However, both the music therapy and expressive reading
interventions resulted in a signiﬁcant reduction in pain and nausea
based on a visual analog scale administered before and after each
session. On Day 7 of transplant, those patients receiving music
therapy had a decrease in patient-requested medication as com-
pared to controls (1.22 vs. 4.27), but there was no signiﬁcant
difference between intervention groups in p.r.n. analgesic admin-
istration. No signiﬁcant difference among groups was found for
frequency of emesis. The relaxation intervention given was not
associated with differences in the levels of selected cytokines (IL-
1a, TNF-a, or interleukin-6) or in absolute lymphocyte counts at
Day 100. This pilot study demonstrates the feasibiltiy of relax-
ation interventions in a stem cell transplant population and begins
to discern possible areas of impact. Further controlled studies are
required to determine (1) whether any speciﬁc effects accrue to
music therapy interventions as compared with other relaxation
interventions, and (2) the role of time and attention, regardless of
speciﬁc activity, on immediate symptom relief.
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DETECTION AND VIRAL LOAD MONITORING OF BK VIRUS IN HEMOR-
RHAGIC CYSTITIS COMPLICATING BONE MARROW TRANSPLANT PA-
TIENTS
Manna, P.1, Wall, D.2, Grimely, M.2, Arnoldi, S.1, Vats, A.3 1.
ViraCor Laboratories, Lee’s Summit, MO; 2. Texas Transplant Insti-
tute/Southwest Texas Methodist Children’s Hospital, San Antonio, TX;
3. Children’s Hospital of Pittsburgh, Pittsburgh, PA
Introduction: Hemorrhagic cystitis causes signiﬁcant morbidity
and mortality in bone marrow transplant (BMT) patients. Recent
reports suggest the association of BK virus (BKV) in BMT patients
with hemorrhagic cystitis due to reactivation of BKV under im-
munosuppressive conditions. Thus, management of serious BKV
Table.
Number of patients 31
Mean age (range) 48 (25-65)
Sex Male 24 (77%), Female 7 (23%)
Underlying disease AML 11 (36%), NHL 7 (22%),
HD 4 (13%), MM 4 (13%), ALL
3 (10%), CML 1 (3%), Germ
cell 1 (3%)
Type of HSCT Auto 28 (90%), Allo 3 (10%)
Mean days of neutropeina
(range)
19 (7-57)
Route of VRC administration PO 15 (49%), IV 10 (32%),
IVPO 6 (19%)
Dose of VRC 400mg q12hr for two doses
then 200mg q 12hr
Mean days of VRC
administration (range)
13 (2-45)
Adverse effects Elevation of LFT’s 2 (6%),
Confusion 1 (3%)
HSCT, hemopoietc stem cell transplant; VRC, voriconazole; AMI,
acute myeloid leukemia; CML, chronic myeloid leukemia;
ALL, acute lymphoid leukemia; MM, multiple myeloma; HD,
Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma; LFT,
liver function test.
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